Abstract.
Glutamic acid decarboxylase (GAD) is considered to be one of the strongest candidate autoantigens involved in triggering β-cell-specific autoimmunity. The majority of recent onset type 1 diabetes patients and prediabetic subjects have anti-GAD antibodies in their sera, as do nonobese diabetic (NOD) mice, one of the best animal models for human type 1 diabetes. Immunization of young NOD mice with GAD results in the prevention or delay of the disease as a result of tolerizing autoreactive T cells. Autoimmune diabetes can also be prevented by the suppression of GAD expression in antisense GAD trans genic mice backcrossed with NOD mice for seven generations. These results support the hypothesis that GAD plays an important role in the development of T-cell-mediated autoimmune diabetes. However, there is some controversy regarding the role of GAD in the pathogenesis of diabetes. Whether GAD truly plays a key role in the initiation of this disease remains to be determined. The examination of the development of insulitis and diabetes in β-cell-specific GAD knockout NOD mice will answer this remaining question.
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received 12 April 2002; received after revision 24 May 2002; accepted 27 May 2002
RID="*"
ID="*"Corresponding author.
Rights and permissions
About this article
Cite this article
Jun, H., Khil, L. & Yoon, J. Role of glutamic acid decarboxylase in the pathogenesis of type 1 diabetes. CMLS, Cell. Mol. Life Sci. 59, 1892–1901 (2002). https://doi.org/10.1007/PL00012512
Issue Date:
DOI: https://doi.org/10.1007/PL00012512